|By PR Newswire||
|December 16, 2013 08:01 AM EST||
NEW YORK, December 16, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Humana Inc. (NYSE: HUM), Illumina Inc. (NASDAQ: ILMN), Forest Laboratories Inc. (NYSE: FRX), Stryker Corp. (NYSE: SYK) and Unilife Corporation (NASDAQ: UNIS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Humana Inc. Research Report
On December 11, 2013, Humana Inc.'s (Humana) stock declined 1.64%, ending the day's session at $101.93. Over the previous three trading sessions, shares of Humana declined 1.99%, compared to the Dow Jones Industrial Average Index, which declined 1.10% during the same period. The Full Research Report on Humana Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Illumina Inc. Research Report
On December 11, 2013, Illumina Inc.'s (Illumina) stock declined 0.71%, ending the day's session at $99.26. Over the previous three trading sessions, shares of Illumina increased 0.01%, compared to the Nasdaq Composite Index, which declined 1.45% during the same period. The Full Research Report on Illumina Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Forest Laboratories Inc. Research Report
On December 9, 2013, Forest Laboratories Inc. (Forest Laboratories) reported new appointments to its executive leadership team, as a part of the Company's plans to flatten and broaden the organization as part of Project Rejuvenate. Brent Saunders, CEO & President of Forest Laboratories, commented, "Today we are announcing an important step to rejuvenate our company by creating the first Forest Executive Team with broad leadership responsibilities, a sharp focus and clear accountability for driving sustainable growth." The Company informed that it has appointed Elaine Hochberg as Executive Vice President, International, Strategic Planning and Government Affairs; Bill Meury as Executive Vice President, Sales and Marketing; Frank Perier, Jr. as Executive Vice President, CFO; Marco Taglietti, MD as Executive Vice President, Drug Development and Research, and Chief Medical Officer; Bob Bailey as Senior Vice President, Chief Legal Officer, General Counsel and Corporate Secretary; Alex Kelly as Senior Vice President, Chief Communications & Investor Relations Officer; Sally Paull as Senior Vice President, Human Resources; Kevin Walsh as Senior Vice President, Operations; and Joe Zimmerman as Senior Vice President, Chief Compliance Officer. Additionally, Forest Laboratories stated that David Solomon, Senior Vice President, Corporate Development and Strategic Planning will serve as Senior Advisor to the CEO responsible for Business Development and Alliance Management on a transitional basis. The Full Research Report on Forest Laboratories Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Stryker Corp. Research Report
On December 4, 2013, Stryker Corp. (Stryker) reported that its Board of Directors has increased its quarterly dividend by 15% to $0.305 per share. According to the Company, shareholders of record at the close of business as on December 31, 2013 will be paid the dividend on January 31, 2014. Kevin A. Lobo, President and CEO of Stryker, commented, "Given our strong balance sheet and cash flow generation, we continue to expand our dividend, which has grown 26% on a compound annual basis since 2008. We remain committed to pursuing acquisitions for growth while also returning capital to shareholders at meaningful levels through dividends and share buybacks." The Full Research Report on Stryker Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Unilife Corporation Research Report
On December 11, 2013, Unilife Corporation's (Unilife) stock increased 6.32%, ending the day's session at $4.54. Over the previous three trading sessions, shares of Unilife increased 5.34%, compared to the Nasdaq Composite Index, which declined 1.45% during the same period. The Full Research Report on Unilife Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner